RACHELLE DOODY to Aged, 80 and over
This is a "connection" page, showing publications RACHELLE DOODY has written about Aged, 80 and over.
Connection Strength
2.234
-
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29.
Score: 0.110
-
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). J Alzheimers Dis. 2025 Jan; 103(2):528-541.
Score: 0.110
-
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. J Prev Alzheimers Dis. 2024; 11(3):537-548.
Score: 0.103
-
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD). J Alzheimers Dis. 2024; 101(1):353-367.
Score: 0.103
-
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. J Prev Alzheimers Dis. 2021; 8(1):3-6.
Score: 0.084
-
Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. J Prev Alzheimers Dis. 2021; 8(2):151-160.
Score: 0.084
-
Different Cognitive Profiles Are Associated with Progression Rate and Age at Death in Probable Alzheimer's Disease. J Alzheimers Dis. 2021; 80(2):735-747.
Score: 0.084
-
Gantenerumab reduces amyloid-? plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019 12 12; 11(1):101.
Score: 0.078
-
Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease. PLoS One. 2016; 11(8):e0160671.
Score: 0.062
-
Prevalence and correlates of cognitive asymmetry in a large sample of Alzheimer's disease patients. J Clin Exp Neuropsychol. 2016; 38(5):516-26.
Score: 0.059
-
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. CNS Spectr. 2016 12; 21(6):450-459.
Score: 0.058
-
Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer's disease: Implications for predicting instrumental activities of daily living. Psychol Assess. 2015 Dec; 27(4):1234-40.
Score: 0.056
-
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21.
Score: 0.052
-
Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis. 2013; 34(2):449-56.
Score: 0.048
-
Factor structure of the Geriatric Depression Scale and relationships with cognition and function in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 34(5-6):360-72.
Score: 0.048
-
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012; 33(2-3):164-73.
Score: 0.046
-
Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores. Alzheimers Dement. 2012 Jul; 8(4):288-94.
Score: 0.046
-
Item response theory reveals variability of functional impairment within clinical dementia rating scale stages. Dement Geriatr Cogn Disord. 2011; 32(5):362-6.
Score: 0.045
-
Greater precision when measuring dementia severity: establishing item parameters for the Clinical Dementia Rating Scale. Dement Geriatr Cogn Disord. 2012; 34(2):128-34.
Score: 0.045
-
Identifying amnestic mild cognitive impairment in primary care: a feasibility study. Clin Drug Investig. 2011; 31(7):483-91.
Score: 0.042
-
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):155-9.
Score: 0.039
-
How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? Dement Geriatr Cogn Disord. 2009; 28(1):63-9.
Score: 0.038
-
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors. Alzheimers Dement. 2009 Mar; 5(2):122-4.
Score: 0.037
-
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 May 05; 72(18):1555-61.
Score: 0.037
-
Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008; 25(2):163-74.
Score: 0.034
-
Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord. 2007; 24(6):476-82.
Score: 0.034
-
Is functional decline necessary for a diagnosis of Alzheimer's disease? Dement Geriatr Cogn Disord. 2007; 24(5):375-9.
Score: 0.033
-
Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005 Mar; 62(3):454-9.
Score: 0.028
-
The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls. Alzheimer Dis Assoc Disord. 2004 Oct-Dec; 18(4):236-40.
Score: 0.027
-
WAIS-R factor structure in Alzheimer's disease patients: a comparison of alternative models and an assessment of their generalizability. Psychol Aging. 2003 Dec; 18(4):836-43.
Score: 0.026
-
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023 Nov 16; 389(20):1862-1876.
Score: 0.026
-
Effects of blood pressure on neuropsychological functioning in Alzheimer's disease. Arch Clin Neuropsychol. 2003 Jan; 18(1):19-32.
Score: 0.024
-
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Jul-Aug; 12(4):295-300.
Score: 0.022
-
Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer's Disease. J Prev Alzheimers Dis. 2021; 8(2):175-180.
Score: 0.021
-
The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. Arch Neurol. 1999 Sep; 56(9):1133-7.
Score: 0.019
-
Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients. Alzheimer Dis Assoc Disord. 1999 Jan; 13(1):53-9.
Score: 0.018
-
Alzheimer disease-related activities in China: a report from the International Working Group on the Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1998 Dec; 12(4):263-5.
Score: 0.018
-
Neuropsychological asymmetry in Alzheimer's disease: verbal versus visuoconstructional deficits across stages of dementia. J Int Neuropsychol Soc. 1997 Sep; 3(5):420-7.
Score: 0.017
-
Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data. J Alzheimers Dis. 2017; 58(2):361-371.
Score: 0.016
-
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017; 58(4):1217-1228.
Score: 0.016
-
Validation of the Spanish version of the Baylor Profound Mental Status Examination. J Alzheimers Dis. 2016; 49(1):73-8.
Score: 0.015
-
Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase. Alzheimers Dement. 2016 Jan; 12(1):75-84.
Score: 0.014
-
Ordered subset analysis of copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2014; 41(4):1063-71.
Score: 0.013
-
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44.
Score: 0.012
-
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013 Jun 06; 13:56.
Score: 0.012
-
The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results. BMC Neurol. 2013 Jan 10; 13:3.
Score: 0.012
-
Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dement Geriatr Cogn Disord. 2014; 37(1-2):45-57.
Score: 0.012
-
Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2013; 33(2):517-23.
Score: 0.012
-
Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease. Transl Psychiatry. 2012 Nov 20; 2:e192.
Score: 0.012
-
The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992 Sep; 55(9):806-10.
Score: 0.012
-
A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011; 6(12):e28092.
Score: 0.011
-
A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord. 2011; 32(1):55-62.
Score: 0.011
-
Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis. 2011; 27(2):259-69.
Score: 0.010
-
Spasmodic dysphonia associated with palatal myoclonus. Ear Nose Throat J. 1990 Dec; 69(12):829-32.
Score: 0.010
-
A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010 Sep; 67(9):1077-81.
Score: 0.010
-
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010 Mar 23; 74(12):956-64.
Score: 0.010
-
Vitamin E use is associated with improved survival in an Alzheimer's disease cohort. Dement Geriatr Cogn Disord. 2009; 28(6):536-40.
Score: 0.010
-
Korean version of the Baylor Profound Mental Status Examination: a brief staging measure for patients with severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(1):69-75.
Score: 0.009
-
Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008 Aug; 65(8):1091-5.
Score: 0.009
-
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008 Mar; 4(2):145-53.
Score: 0.009
-
Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res. 2008 Oct; 42(14):1203-12.
Score: 0.009
-
Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007 Oct 16; 69(16):1622-34.
Score: 0.008
-
Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul 31; 69(5):459-69.
Score: 0.008
-
Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95.
Score: 0.008
-
ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38.
Score: 0.008
-
Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 22(4):367-77.
Score: 0.008
-
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006 Jan; 63(1):49-54.
Score: 0.007
-
Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):178-83.
Score: 0.007
-
Factors affecting deficit awareness in persons with dementia. Dement Geriatr Cogn Disord. 2005; 20(2-3):133-9.
Score: 0.007
-
Accuracy of self-reported depression in persons with dementia. J Am Geriatr Soc. 2005 Mar; 53(3):389-96.
Score: 0.007
-
Dementia Deficits Scale. Rating self-awareness of deficits. Alzheimer Dis Assoc Disord. 2004 Jan-Mar; 18(1):22-31.
Score: 0.006
-
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003 Dec; 60(12):1696-702.
Score: 0.006
-
Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
Score: 0.006
-
Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. Dement Geriatr Cogn Disord. 2002; 13(1):8-12.
Score: 0.006
-
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000 May; 10(3):195-203.
Score: 0.005
-
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11; 158(9):1021-31.
Score: 0.004
-
Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology. 1997 Jul; 49(1):44-50.
Score: 0.004
-
Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 3:46-9.
Score: 0.004